-+ 0.00%
-+ 0.00%
-+ 0.00%

Merck & Company Says FDA Has Approved KEYTRUDA (pembrolizumab) For PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma As Neoadjuvant Treatment, Continued As Adjuvant Treatment Combined With Radiotherapy With Or Without Cisplatin Then As A Single Agent

Benzinga·06/13/2025 10:49:36
Listen to the news

Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1)